HC-1119 is the deuterated compound of enzalutamide, which is a second-generation AR antagonist. Compared to enzalutamide, HC-1119 has lower metabolic rate, higher plasma exposure, and lower brain exposure at equivalent doses in preclinical model. HC-1119 has the potential to be safer and to be used at a lower clinical dose.   HC-1119 program has been adopted into National Major Projects of “Significant New Drugs Creation”. Two phase-III clinical trials are being carried out in China and globally,the NDA application of HC-1119 was accepted by NMPA in November 2023.The investigational product was approved for marketing from the NMPA in China on May 29, 2025.

HP518 is an oral PROTAC drug, with the potential to solve the drug resistance to prostate cancer due to AR variation. HP518 demonstrates good oral exposure and bioavailability in animal model.  HP518 has high activity of degrading wild type AR and variant AR resistant to enzalutamide, high selectivity to AR, and excellent anticancer activity of AR-dependent prostate cancer cells. It also shows obvious effect on prostate cancer animal model. At present HP518 is in Phase I/II clinical study.